Imatinib-induced Stevens-Johnsons syndrome. (23rd January 2013)

• Record Type: Journal Article
• Authors: Jha, Praveen; D, Himanshu; Jain, Nirdesh; Singh, Ajay Kumar
• Is Part Of: BMJ case reports. Volume 2013
• Publication Date: 2013-01-23
• Subjects: Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2012-007926
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Imatinib mesylate is a tyrosine kinase inhibitor used widely as the first-line treatment for chronic myeloid leukaemia (CML). The side-effect profile of this drug includes fluid retention, muscle cramps, diarrhoea, myelosuppression and skin rashes. Of these, rashes of the type maculo-papular eruptions and oedema developed most commonly. The cutaneous adverse reactions other than maculo-papular eruptions are rare with imatinib. Severe and life-threatening cutaneous reactions can occur in 5% cases. Here, the author reports a case of newly diagnosed CML that developed Steven-Johnsons syndrome due to imatinib therapy. Patient responded and discharged successfully on withdrawal of the culminating drug.